Bioceres Crop Solutions Corp.

BASE:BIOX Stock Report

Market Cap: AR$397.7b

Bioceres Crop Solutions Past Earnings Performance

Past criteria checks 2/6

Bioceres Crop Solutions has been growing earnings at an average annual rate of 47.2%, while the Chemicals industry saw earnings growing at 9.8% annually. Revenues have been growing at an average rate of 24.2% per year. Bioceres Crop Solutions's return on equity is 0.8%, and it has net margins of 0.3%.

Key information

47.2%

Earnings growth rate

51.0%

EPS growth rate

Chemicals Industry Growth13.1%
Revenue growth rate24.2%
Return on equity0.8%
Net Margin0.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Bioceres Crop Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BASE:BIOX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24441110217
30 Jun 24465310717
31 Mar 24446310616
31 Dec 234552210416
30 Sep 234091410216
30 Jun 23419199915
31 Mar 23416159513
31 Dec 22391-198811
30 Sep 22389-8789
30 Jun 22328-7657
31 Mar 22308-2587
31 Dec 212754526
30 Sep 212311466
30 Jun 21207-7456
31 Mar 21174-5374
31 Dec 20164-7354
30 Sep 201783344
30 Jun 201723334
31 Mar 201740365
31 Dec 19167-18365
30 Sep 19167-23364
30 Jun 19160-18344
31 Mar 19142-26293
31 Dec 18145-8283
30 Sep 18129-13294
30 Jun 18133-11314
30 Jun 1794-12274
31 Dec 1641-681
31 Dec 155-110

Quality Earnings: BIOX has high quality earnings.

Growing Profit Margin: BIOX's current net profit margins (0.3%) are lower than last year (3.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BIOX has become profitable over the past 5 years, growing earnings by 47.2% per year.

Accelerating Growth: BIOX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BIOX had negative earnings growth (-89.3%) over the past year, making it difficult to compare to the Chemicals industry average (2.5%).


Return on Equity

High ROE: BIOX's Return on Equity (0.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bioceres Crop Solutions Corp. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian Kemp DolliverBrookline Capital Markets
Austin MoellerCanaccord Genuity
Benjamin KlieveLake Street Capital Markets, LLC